|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Akero Therapeutics insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Akero Therapeutics insider buys are important for investors to follow.
Date | Insider | Price | Amount |
12-8-2023 Insider Buy |
G. Walmsley Graham
|
$19.83
CAGR »
|
$1,982,940.00 100,000 shares |
12-1-2023 Insider Buy |
G. Walmsley Graham
|
$16.95
CAGR »
|
$1,694,565.00 100,000 shares |
8-8-2023 Insider Buy |
G. Walmsley Graham
|
$42.06
CAGR »
|
$1,051,475.00 25,000 shares |
8-1-2023 Insider Buy |
G. Walmsley Graham
|
$42.95
CAGR »
|
$2,362,234.00 55,000 shares |
5-19-2023 Insider Buy |
G. Walmsley Graham Director |
$29.69
CAGR »
|
$15,440,000.00 520,000 shares |
7-10-2020 Insider Buy |
Apple Tree Partners IV, L.P. >10% Owner |
$36.00
CAGR »
|
$14,940,000.00 415,000 shares |
7-10-2020 Insider Buy |
Seth Loring Harrison Director and >10% Owner |
$36.00
CAGR »
|
$14,940,000.00 415,000 shares |
6-24-2019 Insider Buy |
Apple Tree Partners IV, L.P. >10% Owner |
$16.00
CAGR »
|
$14,400,000.00 900,000 shares |
6-24-2019 Insider Buy |
Seth Loring Harrison Director and >10% Owner |
$16.00
CAGR »
|
$14,400,000.00 900,000 shares |
6-24-2019 Insider Buy |
Aaron Royston Director |
$16.00
CAGR »
|
$4,000,000.00 250,000 shares |
6-24-2019 Insider Buy |
Atlas Venture Fund XI, L.P. >10% Owner |
$16.00
CAGR »
|
$4,320,000.00 270,000 shares |
6-24-2019 Insider Buy |
Kevin Bitterman Director |
$16.00
CAGR »
|
$4,320,000.00 270,000 shares |
6-24-2019 Insider Buy |
Global Strategic Fund L.P. Venbio II >10% Owner |
$16.00
CAGR »
|
$4,000,000.00 250,000 shares |
Also See: Institutional Holders of AKRO
Also See: SEC filings
Below we present the annualized performance delivered by Akero Therapeutics stock since 12-8-2023 (the date of the most recent
insider purchase). The performance of the investment from the time Akero Therapeutics insider buying occurred is the ultimate
test of whether insiders were right about AKRO being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
12/11/2023 |
|
End date: |
05/02/2024 |
|
Start price/share: |
$19.45 |
|
End price/share: |
$19.71 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
1.34% |
|
Annualized Gain: |
3.44% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$10,134.00 |
|
Years: |
0.39 |
|
Akero Therapeutics Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Akero Therapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding AKRO
|
|